China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…

USA Although Boston and California may be more internationally renowned as biotech hubs, New York is fast catching up. Thanks in large part to its strong scientific and business infrastructure and easy access to capital, growing numbers of early-stage biotechs are choosing to base their operations in New York and list…

France With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing up a national strategy on artificial intelligence (AI) in his capacity as Chargé de Mission, there is little doubting the…

France France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of expertise and increasing political support. However, financing and manufacturing French gene therapies is proving an issue, meaning that France is…

France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…

Korea Industry players – from Big Pharma giants to small local startups – are bringing new, innovative solutions to market in Korea in order to try and solve the country’s diabetes epidemic.   The growing prevalence of Type 2 Diabetes is becoming a global issue. According to Dr Nam Han Cho,…

Korea The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how.   Once we chose to specialise in biosimilars, there was no room to survive if we failed with the few projects…

Korea ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s long-standing expertise in chemicals.   We have penetrated the Korean market already, and have received approval in 12 overseas emerging…

CEO Profile CEO of the Life Science division of LG – one of Korea most recognized global brands – Dr Jeewoong Son has spent much of his career gathering the knowhow to bring successful drug development to Korea.   “I began my career as physician in internal medicine before moving to a…

Opinion Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and…

Opinion Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big Pharma to adopt this technology more fully.   The beauty of artificial intelligence is that it allows one to assess both forest and tree.   A…

China Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an R&D-focused innovation centre, and a brand awareness drive for both consumers and potential future employees.   The Chinese medical aesthetics…